Removal of syndecan-1 promotes TRAIL-induced apoptosis in myeloma cells

Journal of Immunology

Volumn 188, Issue 6, 2012, Pages 2914-2921

  Wu, Yung Hsuan ^a,b   Yang, Chen Ying ^a,b   Chien, Wen Li ^a,b   Lin, Kuo I ^c   Lai, Ming Zong ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FAS LIGAND; HEPARAN SULFATE; SMALL INTERFERING RNA; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GLYCOSYLATION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SYNDECAN-1; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84863252852     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102065     Document Type: Article

References (39)

1. Bernfield, M., M. Götte, P. W. Park, O. Reizes, M. L. Fitzgerald, J. Lincecum, and M. Zako. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68: 729-777. (Pubitemid 29449208)
2. Couchman, J. R. 2003. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat. Rev. Mol. Cell Biol. 4: 926-937. (Pubitemid 37493641)
3. Kramer, K. L., and H. J. Yost. 2003. Heparan sulfate core proteins in cell-cell signaling. Annu. Rev. Genet. 37: 461-484. (Pubitemid 38043946)
4. Bishop, J. R., M. Schuksz, and J. D. Esko. 2007. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446: 1030-1037. (Pubitemid 46676065)
5. Couchman, J. R. 2010. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 26: 89-114.
6. Derksen, P. W., R. M. Keehnen, L. M. Evers, M. H. van Oers, M. Spaargaren, and S. T. Pals. 2002. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99: 1405-1410. (Pubitemid 34547098)
7. O'Connell, M. P., J. L. Fiori, E. K. Kershner, B. P. Frank, F. E. Indig, D. D. Taub, K. S. Hoek, and A. T. Weeraratna. 2009. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J. Biol. Chem. 284: 28704-28712.
8. Sanderson, R. D., and Y. Yang. 2008. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25: 149-159.
9. Shaffer, A. L., M. Shapiro-Shelef, N. N. Iwakoshi, A. H. Lee, S. B. Qian, H. Zhao, X. Yu, L. Yang, B. K. Tan, A. Rosenwald, et al. 2004. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21: 81-93. (Pubitemid 38925269)
10. Shapiro-Shelef, M., and K. Calame. 2005. Regulation of plasma-cell development. Nat. Rev. Immunol. 5: 230-242. (Pubitemid 40364824)
11. Yang, Y., V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al. 2007. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110: 2041-2048. (Pubitemid 47443921)
12. Khotskaya, Y. B., Y. Dai, J. P. Ritchie, V. MacLeod, Y. Yang, K. Zinn, and R. D. Sanderson. 2009. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 284: 26085-26095.
13. Beauvais, D. M., B. J. Ell, A. R. McWhorter, and A. C. Rapraeger. 2009. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 206: 691-705.
14. Peter, M. E., R. C. Budd, J. Desbarats, S. M. Hedrick, A. O. Hueber, M. K. Newell, L. B. Owen, R. M. Pope, J. Tschopp, H. Wajant, et al. 2007. The CD95 receptor: apoptosis revisited. Cell 129: 447-450. (Pubitemid 46660984)
15. Strasser, A., P. J. Jost, and S. Nagata. 2009. The many roles of FAS receptor signaling in the immune system. Immunity 30: 180-192.
16. Wilson, N. S., V. Dixit, and A. Ashkenazi. 2009. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 10: 348-355.
17. Micheau, O., and J. Tschopp. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114: 181-190. (Pubitemid 36936912)
18. Schneider-Brachert, W., V. Tchikov, J. Neumeyer, M. Jakob, S. Winoto-Morbach, J. Held-Feindt, M. Heinrich, O. Merkel, M. Ehrenschwender, D. Adam, et al. 2004. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21: 415-428. (Pubitemid 39208342)
19. Wang, L., F. Du, and X. Wang. 2008. TNF-a induces two distinct caspase-8 activation pathways. Cell 133: 693-703. (Pubitemid 351636305)
20. Parlato, S., A. M. Giammarioli, M. Logozzi, F. Lozupone, P. Matarrese, F. Luciani, M. Falchi, W. Malorni, and S. Fais. 2000. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19: 5123-5134.
21. Granés, F., J. M. Urena, N. Rocamora, and S. Vilaró. 2000. Ezrin links syndecan- 2 to the cytoskeleton. J. Cell Sci. 113: 1267-1276.
22. Ashkenazi, A., and R. S. Herbst. 2008. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118: 1979-1990. (Pubitemid 351872316)
23. Johnstone, R. W., A. J. Frew, and M. J. Smyth. 2008. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8: 782-798.
24. Falschlehner, C., T. M. Ganten, R. Koschny, U. Schaefer, and H. Walczak. 2009. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol. 647: 195-206.
25. Testa, U. 2010. TRAIL/TRAIL-R in hematologic malignancies. J. Cell. Biochem. 110: 21-34.
26. Abdulghani, J., and W. S. El-Deiry. 2010. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14: 1091-1108.
27. Gazitt, Y., P. Shaughnessy, and W. Montgomery. 1999. Apoptosis-induced by TRAIL AND TNF-α in human multiple myeloma cells is not blocked by BCL-2. Cytokine 11: 1010-1019. (Pubitemid 30045340)
28. Chen, Q., B. Gong, A. S. Mahmoud-Ahmed, A. Zhou, E. D. Hsi, M. Hussein, and A. Almasan. 2001. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98: 2183-2192.
29. Mitsiades, C. S., S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson. 2001. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804.
30. Kuo, W. C., K. T. Yang, S. L. Hsieh, and M. Z. Lai. 2010. Ezrin is a negative regulator of death receptor-induced apoptosis. Oncogene 29: 1374-1383.
31. Lin, F. R., H. K. Kuo, H. Y. Ying, F. H. Yang, and K. I. Lin. 2007. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. Cancer Res. 67: 11914-11923.
32. Reijmers, R. M., R. W. Groen, H. Rozemuller, A. Kuil, A. de Haan-Kramer, T. Csikós, A. C. Martens, M. Spaargaren, and S. T. Pals. 2010. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115: 601-604.
33. Austin, C. D., D. A. Lawrence, A. A. Peden, E. E. Varfolomeev, K. Totpal, A. M. De Mazière, J. Klumperman, D. Arnott, V. Pham, R. H. Scheller, and A. Ashkenazi. 2006. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl. Acad. Sci. USA 103: 10283-10288. (Pubitemid 44051158)
34. Kohlhaas, S. L., A. Craxton, X. M. Sun, M. J. Pinkoski, and G. M. Cohen. 2007. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282: 12831-12841. (Pubitemid 47100635)
35. Wagner, K. W., E. A. Punnoose, T. Januario, D. A. Lawrence, R. M. Pitti, K. Lancaster, D. Lee, M. von Goetz, S. F. Yee, K. Totpal, et al. 2007. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13: 1070-1077. (Pubitemid 47517508)
36. Sato, T., S. Irie, S. Kitada, and J. C. Reed. 1995. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268: 411-415.
37. Schickel, R., S. M. Park, A. E. Murmann, and M. E. Peter. 2010. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 38: 908-915.
38. Lozupone, F., L. Lugini, P. Matarrese, F. Luciani, C. Federici, E. Iessi, P. Margutti, G. Stassi, W. Malorni, and S. Fais. 2004. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 279: 9199-9207. (Pubitemid 38295983)
39. Ikeda, H., T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. 2009. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15: 4028-4037.